Uncovering the Truth: ISS Relies on MindMed’s Deceptive Statements to Excuse Poor Performance and Neglect of Patient Safety
ISS Dismissed 47% Stock Price Drop Following September 2022 Financing as In Line with “Sectoral Trends” In a Baffling Lack of Critical Analysis and Seemingly in Opposition to the Factual Circumstances After Recommending Removal of Chair Vallone in 2022, ISS Appears to Blindly Accept Vallone’s and MindMed’s Justifications for Poor Development Decisions, Destructive Financing, and……